What are mesenchymal stromal cells?
Mesenchymal stromal cells — often called MSCs — are a diverse group of cells studied for immunomodulatory, signalling and tissue-support functions. They may be obtained from sources such as bone marrow, adipose tissue or perinatal tissue. The term does not describe one uniform medicine.
The same abbreviation can refer to products with different donors, culture methods, passage numbers, release tests, doses, routes and clinical purposes. Patients should therefore avoid comparing offers only by “number of cells.”
Source and preparation matter
Bone marrow
May be autologous or donor-derived. Collection and patient age can affect the pathway.
Adipose tissue
Usually involves tissue collection and specialised processing; terminology can be inconsistent.
Umbilical cord
Donor-derived and typically manufactured as an allogeneic product; donor and batch controls matter.
Other tissues
Products from placenta or other sources require the same exacting identity and evidence questions.
What MSCs may and may not do
Many proposed MSC mechanisms involve secreted signals, immune modulation and support of local repair rather than simply “turning into a new organ.” Mechanistic claims should not be confused with proven patient outcomes.
Evidence varies widely by condition. A study in knee osteoarthritis cannot automatically justify use for diabetes, pulmonary disease, neurologic disease or healthy aging. The exact indication must be reviewed.
Safety is product- and patient-specific
Potential risks can include infusion reactions, infection, immune effects, clotting or embolic complications, procedure-related harm and risks that are not yet fully known. Patient comorbidities, route of administration and manufacturing quality affect the risk profile.
What to request
Ask for product identity, source, manufacturing entity, sterility and release testing, route, dose, adverse-event plan and the medical team responsible for follow-up.
How we review an MSC offer
We compare the provider’s language with the actual condition, institution and clinical route. We also check whether the quotation clearly distinguishes hospital treatment from coordination and whether claims are supported by indication-specific evidence.